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The Crim1 gene is predicted to encode a transmem-
brane protein containing six von Willebrand-like cys-
teine-rich repeats (CRRs) similar to those in the BMP-
binding antagonist Chordin (Chrd). In this study, we
verify that CRIM1 is a glycosylated, Type I transmem-
brane protein and demonstrate that the extracellular
CRR-containing domain can also be secreted, presum-
ably via processing at the membrane. We have previ-
ously demonstrated Crim1 expression at sites consistent
with an interaction with bone morphogenetic proteins
(BMPs). Here we show that CRIM1 can interact with
both BMP4 and BMP7 via the CRR-containing portion of
the protein and in so doing acts as an antagonist in three
ways. CRIM1 binding of BMP4 and -7 occurs when these
proteins are co-expressed within the Golgi compartment
of the cell and leads to (i) a reduction in the production
and processing of preprotein to mature BMP, (ii) teth-
ering of pre-BMP to the cell surface, and (iii) an effective
reduction in the secretion of mature BMP. Functional
antagonism was verified by examining the effect of co-
expression of CRIM1 and BMP4 on metanephric explant
culture. The presence of CRIM1 reduced the effective
BMP4 concentration of the media, thereby acting as a
BMP4 antagonist. Hence, CRIM1 modulates BMP activ-
ity by affecting its processing and delivery to the cell
surface.
The TGF1 superfamily of ligands have prominent roles in
nearly all tissues during development. There are over 30 mem-
bers of this superfamily, including the TGF isoforms, bone
morphogenetic proteins (BMPs), and the closely related growth
and differentiation factors, activins, and nodals (reviewed in
Ref. 1). BMPs, like all members of the TGF superfamily, are
synthesized as preproteins, which are subsequently cleaved by
furin and related subtilisin-like convertases within the Golgi
apparatus at a conserved multibasic amino acid motif (Arg-X-
X-Arg) to yield a dimeric C-terminal mature domain (2). Once
secreted BMPs bind and facilitate the formation of heteromeric
complexes of type I and type II serine/threonine kinase recep-
tors (1). These signal via phosphorylation of Smad proteins,
which can translocate into the nucleus and effect gene regula-
tion and expression (reviewed in Ref. 1). Although TGF-1, -2,
and -3 are secreted as a member of a large inactive complex
containing the latency-associated peptide and a latent TGF-
binding protein, the BMPs are currently thought to be pro-
cessed and secreted as active mature molecules and not com-
plexed with a latent TGF-binding protein-like molecule.
However, like the TGFs, BMPs do not seem to act over a range
of more than one to two cells, suggesting that there is some
mechanism of “tethering” (3). This limit in signaling range is in
part influenced by the prodomain of BMPs (3). The prodomain
of the BMPs also influences the efficiency of processing and the
stability of the mature BMP (2, 4). During development, TGF
superfamily members, and in particular BMPs, specify cell
types by forming precisely controlled concentration gradients.
The amount of active ligand is regulated via modulation of
protein processing, receptor binding, regulation of Smad func-
tion, and, as has been discovered recently, extracellular antag-
onism of BMPs. One of the extracellular BMP antagonists is
Chordin (Chrd) and its homologue in Drosophila, short gastru-
lation (sog) (5–8). The Chordin protein (CHRD) is a dorsalizing
factor expressed by the organizer in Xenopus, which functions
by directly binding BMP4 to inhibit its receptor binding (5, 8).
Sog, the functional homologue of Chrd in Drosophila, is ex-
pressed ventrally and partly establishes the dorso-ventral body
axis by inhibiting the activity of dpp (most closely related to
vertebrate BMP2/4) (6). Overexpression of SOG protein can
inhibit BMP4 signaling in Xenopus, revealing functional con-
servation of this interaction between vertebrates and inverte-
brates (7). The BMP-antagonizing activity of CHRD and SOG is
itself regulated via secreted metalloproteases related to BMP1
(9, 10). Xolloid in Xenopus cleaves CHRD, effectively abolishing
its ability to antagonize BMP4 (9). Tolloid functions in a similar
way in Drosophila to cleave SOG (10).
CHRD and SOG proteins are characterized by multiple cys-
teine-rich repeats, similar to the von Willebrand Factor type C
domain (5). Such cysteine-rich repeats (CRRs) have a
conserved consensus sequence based on ten cysteines
(CXnWX4CX2CXCX6CX4CX4–6CX9–11CCPXC). Specific indi-
vidual CRRs in CHRD can bind directly to BMP4 (11). Re-
cently, a number of novel CRR-containing proteins have been
identified, including Neuralin1 (also known as Ventropin) (12–
14), Drosophila Crossveinless2 (15), and Xenopus Kielen (16).
Although possessing varying numbers of CRRs, all of these
proteins bind to BMPs. CRR motifs in other proteins mediate
binding to other members of the TGF superfamily. The CRR of
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procollagen type IIA can interact with TGF2 and BMP2 (11,
17). It has therefore been speculated that this domain has
evolved to modulate interactions with TGF superfamily mem-
bers (11). Connective tissue growth factor contains one CRR
and has been shown to antagonize BMP4 by inhibiting receptor
binding but acts synergistically with TGF1 to enhance recep-
tor binding (18). Therefore this novel family of proteins appear
critical in regulating the activity of TGF/BMP signaling in
development.
The Crim1 gene encodes a protein with six chordin-like
CRRs, an N-terminal insulin-like growth factor binding pro-
tein-like motif and a putative transmembrane domain (19). By
analogy to other CRR proteins, we have hypothesized that
CRIM1 may also function as an antagonist to one or more
members of the TGF superfamily by direct binding via the
CRR repeats (19). Crim1 shows developmentally regulated ex-
pression in the mouse embryo localized to the developing kid-
ney and testis (20), the lens of the eye (21), vibrissae, pinna,
tooth primordia, as well as specific regions within the central
nervous system (19). A study of the spatial and temporal ex-
pression of Crim1, BMP2, and BMP7 during mouse urogenital
development, showed a pattern of overlapping expression for
these proteins implying a possible physiological interaction
(20). Here we show that CRIM1 interacts with members of the
TGF family, including BMP4 and BMP7, when co-expressed
with these growth factors and that this interaction occurs via
the CRR repeat domains. Co-expression of CRIM1 with BMP4
or BMP7 results in a reduction in the processing of pre-BMPs
to their mature form and a consequent reduction in the amount
of BMP secretion. However, CRIM1 is trafficked with its pre-
protein ligand to the plasma membrane, whereupon a propor-
tion of the complex remains tethered to the cell surface in an
inactive preprotein form. Hence CRIM1 can antagonize mem-
bers of the TGF superfamily.
EXPERIMENTAL PROCEDURES
Construction of Mammalian Expression Vectors—A full-length hu-
man CRIM1 (GenBankTM accession number AF167706) expression con-
struct was created from existing subclones, which covered the entire
open reading frame of CRIM1. Intrinsic PmeI and DraII restriction
enzyme sites were used for insertion into pCDNA3. An myc (EQKLI-
SEEDL) or HA (YPYDVPDY) tag was introduced into CRIM1-Nmyc/HA
constructs after residue 78 (Phe) by PCR. CRIM1-E was made by
truncating the protein at residue 901, and inserting an myc or HA tag
at the C terminus. BMP7preHA was derived from mouse BMP-7
(pMTAD1-BMP7myc, a gift of Dr. Elizabeth Robertson) by inserting the
HA epitope after residue 87 (Tyr) as a linker in an intrinsic BsrGI site.
Other constructs used in this study were human BMP4 (PMT21-
BMP4myc, a gift of Dr. Tom Jessell), chicken Chordin (pMT21-CHRDHA,
a gift of Dr. Kevin Lee), and human growth hormone receptor
(pcDNA3-GHRHA , a gift of Prof. Michael Waters).
Generation of Anti-CRIM1 Antibodies—Polyclonal antibodies were
raised and purified as described previously (26). -NC was raised to-
ward a synthetic peptide: KVCQPGYLNILVSKASGKPGEC (Chiron
Technologies). -CC was raised toward a glutathione S-transferase-
conjugated C-terminal epitope of mouse CRIM1 (residues 998–1036;
GenBankTM accession number AF168680), which was cloned into pGEX
as described previously (26).
Cell Culture and Transfections—COS7 cells were transfected when
at 50–70% confluence with 1 g of DNA (or as indicated), in 3 l of
FuGENE6 (Roche Applied Science). Transfected cells were incubated in
Dulbecco’s modified Eagle’s medium plus 10% fetal calf serum or OPTI-
MEM (Invitrogen) for serum-free conditions for 2–3 days. Conditioned
media was harvested and concentrated 10 using Amicon Ultra con-
centraters (Millipore).
Cell Fractionation and Western Blotting—CRIM1-Nmyc-transfected
COS7 cells were fractionated into light membrane, heavy membrane,
and soluble fractions as previously described (22). Western blotting, of
fractionated samples, cellular extracts, or media as described below,
was performed as described previously (26).
Immunofluorescence of Cells—Immunofluorescence on cell lines us-
ing the antibodies indicated was performed as described previously for
permeabilized cells (26). For cell surface binding, antibody incubations
were performed on live cells incubated on ice to inhibit internalization.
Cells were finally fixed in 4% paraformaldehyde for 30 min. Antibody
labeling was captured on an Olympus AX70 compound fluorescence
microscope.
Protein Expression and Glycosylation Assay—For production of
CRIM1, CHRD, BMP4, or BMP7 for in vitro binding studies, transiently
transfected COS7 cells were incubated in serum-free OPTI-MEM (In-
vitrogen) for 2 days. Conditioned media was concentrated 1:10 and
snap-frozen. Conditioned media from transfections using pcDNA3 with-
out insert were used as a control. CRIM1-E protein was expressed by
using a stable Chinese hamster ovary cell line. The protein was purified
from conditioned media on an -myc affinity column. The -myc pro-
duced by the hybridoma 9E10 was cross-linked to protein A-agarose
(Sigma) using the method supplied with the cross-linker (Pierce). Pro-
tein concentrations were estimated against samples of known concen-
tration by Western blotting. N-Glycosidase S was used to determine
N-linked glycosylation according to the manufacturer’s instructions
(Roche Applied Science).
Immunoprecipitation—For in vitro binding experiments, conditioned
concentrated media (see above) were incubated in 200 l of 0.5% bovine
serum albumin, 5 mM Tris-HCl, pH 8.0, for 3 h on ice. Cross-linking was
performed where indicated using disuccinimidyl suberate (Pierce) ac-
cording to the manufacturer’s instructions. For immunoprecipitation of
co-expressed samples, media was used without concentration. Immu-
noprecipitations were performed by the addition of 5 l of -myc anti-
body and a 2-h incubation at room temperature, followed by the addi-
tion of 40 l of protein A-Sepharose (50% slurry, Sigma) and a further
1-h incubation. The beads were pelleted and washed four times with
PBS 0.1% Triton X-100 and once with PBS. Protein was eluted by
addition of SDS-PAGE loading buffer (0.625 M Tris-HCl, pH 6.8, 4%
SDS, 10% -mercaptoethanol, 40% glycerol, 0.05% bromphenol blue)
and boiled for 5 min. For cellular extracts, transfected cells were sus-
pended in 600 l of lysis buffer (0.05 M Tris, 0.15 M NaCl, pH 8.5,
Complete protease inhibitors (Roche Applied Science), 0.5% Triton
X-100). Immunoprecipitation was carried out as above, except that
beads were pelleted and washed in lysis buffer three times, and twice in
PBS.
Biotinylation—Cell surface proteins were biotinylated using EZ-Link
Sulfo-NHS-LC-Biotin according to the manufacturer’s instructions
(Pierce).
Explant Culture—Embryonic mouse kidneys were dissected at 11.5
days postcoitum (dpc) and grown in culture medium containing Dulbec-
co’s modified Eagle’s medium/F-12, 20 mM glutamine, 5 g/ml holo-
Transferrin as described in a previous study (27). Conditioned medium
(5 l) was added where indicated. For immunofluorescence analyses,
explants were fixed in 100% ice-cold methanol, 10 min, washed in PBS,
and permeabilized with 1% Triton X-100 in PBS. Antibody incubations
were performed for 1 h at 37 °C in 1% bovine serum albumin in PBS.
Primary antibodies used were WT1 (DAKO, 1/100 dilution) and calbi-
ndin 28K (Sigma, 1/200 dilution). Secondary antibodies were Cy3-con-
jugated anti-rabbit IgG and Alexa-conjugated anti-mouse IgG. Ureteric
tip and nephron number were counted manually, and statistics were
performed using InStat3. Due to variability in the age of explants
between litters, one-way analysis of variance could only be performed
within a given experiment.
RESULTS
CRIM1 Is a Type I Transmembrane Protein—Sequence anal-
ysis of the CRIM1 open reading frame reveals a C-terminal
transmembrane domain, suggesting the large N-terminal CRR-
containing domain localizes in the extracellular space (19). To
test this, we designed mammalian expression constructs of
human full-length CRIM1, differentially tagged with myc or
HA epitope tags (CRIM1-Nmyc/HA). We also produced myc- and
HA-tagged constructs with a deletion of the potential trans-
membrane domain and C-terminal sequence (CRIM1-Emyc/HA)
(Fig. 1A). Polyclonal antibodies were raised in rabbits to
epitopes in the N and C termini of CRIM1 (-NC and -CC,
respectively) (Fig. 1A). Western blotting with -myc, -NC, and
-CC of cellular extracts of COS7 cells transfected with the
CRIM1 constructs identified bands of 140 kDa for CRIM1-
Nmyc and 120 kDa for CRIM1-Emyc (Fig. 1, B and C). CRIM1-E
was detected with the -NC antibody (Fig. 1C), but the -CC
epitope is deleted in this construct. A sequence of LVXLPX-
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DESK (where X is presumably cysteine) was obtained after
N-terminal amino acid sequencing of purified CRIM1-E, which
confirms a functional signal peptide sequence with a cleavage
site between amino acids Ala-34 and Leu-35.
To analyze subcellular localization we fractionated CRIM1-
transfected cells to determine if it was localized to membrane
fractions. CRIM1 was detected predominantly in the light
membrane fraction, which corresponds to the plasma mem-
brane compartment. A smaller concentration was evident in
the heavy membrane fraction, which corresponds to intracellu-
lar trafficking compartments (Fig. 1D) (22). To examine poten-
tial plasma membrane localization and orientation, we ana-
lyzed CRIM1-Nmyc transfected cells by immunofluorescence. In
transfected cells that had been permeabilized by treatment
with Triton X-100, there was a strong signal from antibodies to
the N-terminal domain (-myc) and the C-terminal domain
(-CC) (Fig. 1, E and F). Without permeabilization, only the
N-terminal domain appeared to be accessible to antibody bind-
ing, suggesting the C-terminal was located within the cell (Fig.
1, G and H). In cells transfected with the deletion construct
CRIM1-E, no cell surface localization of CRIM1-E was evident
(Fig. 1J), yet immunofluorescence of permeabilized cells clearly
showed the protein was expressed (Fig. 1I), suggesting that
without the transmembrane domain CRIM1 is secreted. There-
fore the CRIM1 protein adopts a type I transmembrane confor-
mation with the cysteine-rich N-terminal end localized to the
extracellular space (Fig. 1K).
CRIM1 Can Be Cleaved to Secrete a Soluble Ectodomain—
Because CHRD and other CRR-containing proteins encode se-
creted molecules, we determined whether a secreted form of
CRIM1 exists. Media harvested from COS7 cells transfected
with full-length CRIM1 (CRIM1-Nmyc) showed a small amount
of CRIM1 in the media (Fig. 1B). The molecular mass of this
form was found to be 10–15 kDa smaller than from cellular
lysates. Although CRIM1-Nmyc from cell lysates was able to be
immunoprecipitated by both -NC and -CC CRIM1 antibod-
ies, only the -NC antibody was able to immunoprecipitate the
secreted form of CRIM1-Nmyc from the conditioned media (Fig.
1L). These results suggest that CRIM1 is cleaved to release the
N-terminal cysteine-rich ectodomain.
CRIM1 Is N-Glycosylated—Careful analysis of cell lysates
and media from COS7 cells transfected with CRIM1-Emyc sug-
FIG. 1. CRIM1 is a glycosylated type I transmembrane protein. A, ideogram of CRIM1 expression vectors. Full-length (CRIM1-Nmyc/HA)
and C-terminal deleted CRIM1 constructs (CRIM1-Emyc/HA) were tagged with myc or HA epitopes (arrows indicate epitope tag insertions). Regions
to which polyclonal antibodies -NC and -CC were raised are indicated. B, the polyclonal antibodies -CN and -CC detected CRIM1 and
CRIM1-E protein in COS7 cells transfected with these constructs but not in COS7 cells transfected with pcDNA3 only (Mock). C, CRIM1-Nmyc and
CRIM1-Emyc protein was detected in cell lysates and conditioned media from COS7 cells transfected with these constructs by Western blotting
using -myc. A stronger band was observed in the media with transfection of CRIM1-Emyc than CRIM1-Nmyc. Note the size difference observed for
CRIM1 in cell lysate (140 kDa) versus media (120 kDa) (arrows). D, CRIM1-Nmyc protein was detected predominantly in the light (L) membrane
fraction of fractionated COS7 cells transfected with CRIM1-Nmyc, with a small amount in the heavy (H) membrane fractions, but was not detected
in the soluble (S) fraction. E–H, CRIM1 is localized on the plasma membrane with the N-terminal region in the extracellular space. CRIM1-Nmyc-
transfected COS7 cells, permeabilized with Triton X-100 (TX) (E and F) or non-permeabilized (TX) (G and H), were stained with either -myc
(E and G) or -CC (F and H). The C-terminal region of CRIM1 was not detected in non-permeabilized cells (H). I and J, CRIM1-E does not associate
with the plasma membrane. COS7 cells transfected with CRIM1-Emyc were either permeabilized (I) or not (J) and stained with -myc. K, ideogram
showing the orientation of CRIM1 at the cell-membrane. L, secreted CRIM1 can only be immunoprecipitated with antibodies to the N-terminal
ectodomain. Cell lysates or conditioned media from CRIM1-Nmyc-transfected COS7 cells were immunoprecipitated with -NC or -CC and detected
by Western blotting with -myc. Secreted CRIM1-Nmyc is not immunoprecipitated by -CC suggesting the loss of this epitope. M, CRIM1-secreted
protein is glycosylated. CRIM1-Emyc protein treated with or without N-glycosidase and detected with -myc, revealed a 10-kDa shift in molecular
mass. N, schematic representation of potential N-glycosylation sites (arrows), as assessed by primary sequence analysis.
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gested a minor molecular weight disparity. To determine if this
was due to N-linked glycosylation, we treated CRIM1-Emyc
from media with N-glycosidase. This resulted in a molecular
mass change of 10 kDa suggesting that CRIM1 is N-glycosy-
lated (Fig. 1M). Analysis of the amino acid sequence of CRIM1
suggests that there are five potential N-glycosylation sites
(NX(S/T), where X is not P) in the extracellular domain
(Fig. 1N).
CRIM1 and Members of the TGF Superfamily Can Inter-
act—Strong evidence has suggested that CHRD-like CRR pro-
teins bind to members of the TGF superfamily, particularly
the BMPs (11). Due to the similarity of CRIM1 CRRs to CHRD,
we have focused our analysis on BMP4 (8, 11, 12, 14). We have
also investigated the possibility of interaction with BMP7,
which shows overlapping sites of expression with CRIM1 in the
developing kidney (19, 20). We first tested whether CRIM1
ectodomain protein harvested in media from cells transfected
with CRIM1-EHA or CRIM1-NHA could bind mature BMPs
similarly secreted into the media from BMP-transfected cells.
After incubation of CRIM1 (5–10 nM) and BMP4 or BMP7 (2–10
nM) at room temperature for 1 h, there was no evidence of
binding (Fig. 2A). Under similar binding conditions, CHRD was
co-immunoprecipitated together with BMP4, and weakly with
BMP7 (Fig. 2A), as previously described (8). To exclude the
possibility that the absence of observable binding was due to a
low affinity interaction between CRIM1 and BMP4, chemical
cross-linking of the proteins in solution was also performed.
Although the presence of cross-linked dimeric BMP4, BMP7,
and BMP4CHRD complexes analyzed under reducing condi-
tions showed that the cross-linking was effective, no binding of
CRIM1 to BMP4 was apparent (Fig. 2B). This suggests that the
recombinant CRIM1 ectodomain does not bind BMP4 and
BMP7 directly in solution. We next determined if CRIM1 could
interact with BMPs intracellularly when transiently co-trans-
fected in COS7 cells. CRIM1-NHA was co-immunoprecipitated
with BMP4myc and BMP7myc (Fig. 2C). In addition, the unproc-
essed form of BMP4 (Fig. 2D) was co-immunoprecipitated with
CRIM1-NHA. This suggests that full-length CRIM1 can bind to
the precursor form of BMP4.
Because CRIM1 can be secreted into the media as an ectodo-
main, we determined if this form was still bound to BMPs. Both
CRIM1-EHA and CRIM1-NHA secreted into media were able to
be co-immunoprecipitated with an anti-myc antibody from con-
ditioned media if co-expressed with BMP4myc or BMP7myc (Fig.
2E). CRIM1-Nmyc was only weakly co-immunoprecipitated, but
this may be due to the low amount of secreted CRIM1 (Fig. 1A).
This suggests that CRIM1 can be secreted into the media as a
complex with BMPs.
CRIM1 Associates with BMP7 at the Cell Surface—Because
CRIM1 associates with BMPs in the cell, we used immunoflu-
orescence analysis on non-permeabilized cells to determine if
BMP7myc is tethered to the cell surface when co-expressed with
full-length CRIM1 (CRIM1-NHA). When BMP7 is expressed
alone, or co-expressed with human growth hormone receptor
(GHRHA), there is no BMP7-specific cell surface staining (Fig.
2, F and G). However, when BMP7 was co-expressed with
full-length CRIM1, BMP7 was detected on the cell surface (Fig.
2, H and I). To determine whether CRIM1 was interacting with
FIG. 2. CRIM1 interacts with BMP4 and BMP7 when co-ex-
pressed. A and B, CRIM1 does not bind to BMP4 or BMP7 when
incubated in solution. A, co-immunoprecipitation with -myc of CRIM1
and CHRD (5 nM) with BMP4myc or BMP7myc (2 nM) when incubated
together in vitro. CRIM1-EHA (top panel) is not co-immunoprecipitated
with BMP4 or BMP7. Chordin (CHRDHA) (middle panel) is co-immu-
noprecipitated with BMP4, but only weakly with BMP7. The bottom
panel shows that the BMPmyc proteins were immunoprecipitated with
-myc at equivalent levels. B, cross-linking fails to detect an interaction
between CRIM1 and BMP4 or BMP7. Conditioned media containing
either CRIM1HA, CHRDHA, BMP4myc, or BMP7myc were incubated to-
gether and cross-linking performed. The media were analyzed by SDS-
PAGE under reducing conditions and Western blotting using the anti-
bodies indicated. The top panel shows cross-linked dimeric BMP4 (lane
1) and BMP7 (lane 2) but no evidence of either BMP4 or BMP7 cross-
linked to CRIM1, which would appear as a band at 170 kDa (BMP4
(30 kDa) plus CRIM1 (140 kDa)). BMP4 is cross-linked to CHRD (lane
3). The middle and bottom left panels show BMP4, BMP7, and CRIM1
prior to cross-linking. The bottom right panel shows the cross-linked
BMP4CHRD Western blot from lane 3 reprobed with  HA to detect
CHRD. C and D, CRIM1 can bind BMPs intracellularly when co-trans-
fected in COS7 cells. CRIM1HA is co-immunoprecipitated by BMP4myc
or BMP7myc from cell lysates with -myc (C). The precursor form of
BMP4myc (50 kDa) is co-immunoprecipitated by CRIMHA with -HA (D).
E, CRIM1 is still bound to BMPs when secreted into conditioned media
after co-transfection. CRIM1-EHA (top panel) and CRIM1-NHA (bottom
panel) were co-immunoprecipitated with BMP4 myc and BMP7 myc from
conditioned media from COS7 cells co-transfected with CRIM1-EHA or
CRIM1-NHA and BMP4 or BMP7. F–I, CRIM1, but not growth hormone
receptor, can tether BMPs to the cell surface. Cellular immunofluores-
cence with mouse -HA (F and H) and rabbit -myc (G and I) of
non-permeabilized COS7 cells co-transfected with GHRHA and
BMP7myc (F and G) or with CRIM1-NHA and BMP7myc (H and I). J–K,
BMP7 is tethered to the cell surface as a preprotein. COS7 cells were
co-transfected with BMP7preHA and CRIM1-NHA and cell surface pro-
teins were detected with rabbit -CN (J) and mouse -HA (K).
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the mature or precursor form of BMP7 at the cell surface, an
HA tag was introduced into the N-terminal precursor domain
of the BMP7 construct. Co-immunofluorescence was performed
on non-permeabilized COS7 cells co-transfected with this con-
struct and CRIM1 using a CRIM1 antibody (-CN) and -HA.
The results in Fig. 2 (J and K) show that the BMP7 precursor
was present on the cell surface of CRIM1-expressing cells.
Biotinylation assays were used to investigate the levels of
cell-surface pre-BMP7 in the presence and absence of CRIM1.
COS7 cells were co-transfected with CRIM1 and BMP7 or
empty vector and BMP7. Cell surface proteins were biotiny-
lated and precipitated with streptavidin-agarose. Precipitated
proteins were analyzed by Western blotting and densitometry.
Fig. 3 (A and B) show that the CRIM1-producing cells retained
a higher percentage of pre-BMP7 on the cell surface than
non-expressing cells. To determine whether the tethered pre-
BMP7 can be removed from the cell surface, COS7 cells co-
transfected with CRIM1 and BMP7 or empty vector and BMP7
were subjected to a 5-min PBS wash followed by a 5-min DTT
FIG. 3. CRIM1 binds to BMPs via CRRs and retains BMP7 on
the cell surface. A, COS7 cells were co-transfected with CRIM1myc and
BMP7myc or empty vector and BMP7myc. Cell surface proteins were
biotinylated, precipitated with streptavidin-agarose beads, and ana-
lyzed by Western blotting using -myc. B, pre-BMP7 detected on the
cell surface was quantitated by densitometry. The results are shown as
a percentage of the total pre-BMP7 present in each experiment  S.D.
(n  5). Significantly more pre-BMP7 was present on the cell surface
when co-transfected with CRIM1 (p  0.0002). C, COS7 cells were
co-transfected with CRIM1myc and BMP7myc or empty vector and
BMP7myc. Live cells were subjected to a 5-min wash with PBS or 20 mM
DTT, and the washes were concentrated and analyzed by Western
blotting using -myc. More pre-BMP7 was washed from CRIM1-ex-
pressing cells (top panel) than non-expressing cells (bottom panel). D
and E, the CRR repeats are required for interaction with BMP7. COS7
cells were co-transfected with either CRIM1myc or one of the deletion
constructs (shown schematically in D) and BMP7preHA. CRIM1 or the
deletion constructs were co-immunoprecipitated with BMP7 using 
HA. Immunoprecipitates were analyzed by Western blotting with
-myc. Deletion constructs lacking CRRs (D2 and D4) interact poorly
with BMP7.
FIG. 4. CRIM1 inhibits the co-expression of BMPs. A, COS7 cells
were co-transfected with CRIM1myc or GHRHA and BMP7myc (lanes 1
and 2); CRIM1myc or GHRHA and BMP4myc (lanes 2 and 3); D2 myc or
GHRHA and BMP7myc (lanes 5 and 6). The level of expression of pre-
BMP7 in cell lysates was determined by Western blotting using -myc.
To confirm expression of GHRHA the blot was stripped and reprobed
with -HA. The faint band in lane 5, top panel, is the remains of CRIM1
binding from the initial blot. B, CRIM1 inhibits BMP7 expression in a
dose-dependent manner. COS7 cells were co-transfected with
CRIM1myc (0–3 g of vector DNA) and BMP7myc (1 g of vector DNA).
Cell lysates were analyzed by Western blotting using -myc. C–F,
CRIM1 and BMP7 are trafficked through the Golgi. COS7 cells were
transfected with either CRIM1myc or BMP7myc, permeabilized with
Triton X-100, and co-stained with rabbit, mouse GM130 (a Golgi mark-
er), and secondary antibodies, -rabbit-cy3 and -mouse-Alexa. C and E
show localization of CRIM1 and BMP7, respectively, whereas D and F
show localization of the Golgi in the same cells with GM130. G and H,
CRIM1 and BMP7 co-localize. COS7 cells were co-transfected with
CRIM1HA and BMP7myc, permeabilized, and co-stained with -CN for
CRIM1 (G) and mouse -myc for BMP7 (H). The secondary antibodies
used were -rabbit-cy3 and -mouse-Alexa. Digital images were taken
on both Cy3 and Alexa channels using Image software (National Insti-
tutes of Health).
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(20 mM) wash. The washes were concentrated and analyzed for
the presence of pre-BMP7 by Western blotting. Fig. 3C shows
that a greater amount of pre-BMP7 was washed from the
surface of CRIM1-producing cells, with further pre-BMP7 re-
leased from the CRIM1-producing cells after DTT treatment.
These results are consistent with those of the previous exper-
iment showing that CRIM1-producing cells retain more BMP7
on the cell surface and that the retention involves a conforma-
tion reliant on oxidized cysteine residues.
The CRR Repeats in CRIM1 Interact with BMP7—To deter-
mine whether the CRR repeats are responsible for the interac-
tion of CRIM1 with BMPs, as in CHRD (11), a series of CRIM1
deletion constructs were made (shown schematically in Fig.
3D). These constructs were co-transfected with BMP7 in COS7
cells and the interaction investigated by immunoprecipitation
(Fig. 3E). The constructs in which one of the two CRR domains
were deleted (D2 and D4) interact poorly with BMP7 compared
with the full-length CRIM1 and the other deletion constructs.
These results suggest that the two blocks of CRR repeats,
CRR1–2 and CRR3–6, bind cooperatively to ligand.
CRIM1 Inhibits Expression of BMP4 and BMP7—One unex-
pected observation of CRIM1-BMP co-transfections compared
with BMP transfections alone was that the level of expression
of the BMP4 or BMP7 was reduced when co-expressed with
CRIM1. To confirm that this was a specific effect of CRIM1
expression and not an artifact due to co-expression of two
constructs, COS7 cells were co-transfected with BMP7myc or
BMP4 myc and equimolar amounts of either CRIM1myc, GH-
RHA, or CRIM1-D2 myc. Cell lysates were analyzed by Western
blotting using an -myc antibody and then stripped and rep-
robed with the HA antibody to ensure co-expression of GHRHA.
The level of BMP7 and BMP4 expression in the lysate was
FIG. 5. CRIM1 antagonizes the action of BMP4 by preventing secretion of mature BMP4. COS7 cells were co-transfected with CRIM1myc
and BMP4myc (BMP4 plus CRIM1), DelCRIM1myc and BMP4myc (BMP4 plus D2), BMP4 and empty vector (BMP4), or empty vector alone (control).
The conditioned media from each was concentrated and added to kidney explants for 3 days as described. Immunofluorescence was performed using
rabbit -WT1 and mouse -calbindin D-28K to detect comma and S-shaped bodies (red) and the developing ureteric tree (green), respectively (A,
Crim1; B, BMP4; C, BMP4 plus CRIM1; D, BMP4 plus D2). E and F, quantitation of 12-dpc kidney explant cultures scored for WT1-positive bodies
and ureteric tree tips. Experiments were performed a total three separate occasions with four to seven explants per parameter. Results are shown
as mean counts  S.D. E, explants grown with control and BMP4 plus CRIM1 media possess more tree tips and comma shaped bodies when
compared with explants grown with BMP4 media alone (*, significant difference at p  0.05). F, BMP4 plus D2 conditioned media resulted in a
reduced number of both tips and WT1-positive bodies in comparison to CRIM1 and BMP4 plus CRIM1, but still showed a slightly higher degree
of development than explants cultured with BMP4 conditioned media alone. Explants cultured with CRIM1 alone versus BMP4 plus CRIM1
conditioned media showed no significant difference in ureteric tree tips or WT1-positive bodies. Asterisks within the frame indicate significant
difference between a given parameter and the same parameter when cultured with BMP4 alone. Asterisks below the frame indicate the degree of
significance between the two conditions indicated (ns, not significant; *, p  0.05; **, p  0.01; ***, p  0.001). G, conditioned media from these
experiments was analyzed for BMP4 by Western blotting using -myc. H, BMP4 in the conditioned media from BMP4 alone, BMP4 plus CRIM1
D2, and BMP4 plus CRIM1-expressing cells was quantitated by densitometry. Processed BMP4 in the media was expressed as a percentage of the
total BMP4 in each experiment S.D. (n 4). Each result was found to be significantly different at p 0.05 or less. BMP4 plus CRIM1-expressing
cells secreted less BMP4 than did cells expressing only BMP4. In contrast, CRIM1 D2 plus BMP4-expressing cells secreted an intermediate level
of BMP4 protein.
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reduced markedly when co-expressed with CRIM1 but not with
GHR or with CRIM1 D2 (Fig. 4A). COS7 cells were co-trans-
fected with BMP7 and increasing concentrations (0.5–3 g) of
CRIM1 construct. Analysis of the conditioned media showed
that secretion of BMP7 was reduced in a dose-dependent man-
ner with increasing concentration of CRIM1 (Fig. 4B).
CRIM1 Co-localizes with BMP7 Intracellularly—Because
CRIM1 appeared to interact with the BMPs intracellularly
during processing, it would follow that the two proteins should
be trafficked through the same intracellular compartments.
Immunofluorescence of permeabilized COS7 cells that had
been transfected with either CRIM1HA or BMP7 myc showed
co-localization of these proteins with GM130, a Golgi-specific
antibody (Fig. 4, C–F). COS7 cells co-transfected with
CRIM1HA and BMP7myc showed marked co-localization (Fig. 4,
G and H).
Taken together our results suggest that CRIM1 interacts
with the BMP7 precursor intracellularly, and this interaction
results in decreased production of BMPs. The interaction with
pre-BMPs appears to be maintained during trafficking of
CRIM1 to the cell surface, where pre-BMP7 remains tethered
to the cell surface.
CRIM1 Antagonizes BMP4—To examine the functional ef-
fect of CRIM1 tethering pre-BMP to the cell surface we used a
kidney explant assay. BMP4 is known to retard the develop-
ment of embryonic mouse kidneys grown in culture in a dose-
dependent manner (23). Kidneys were dissected from embry-
onic mice at 11.5 or 12 dpc and were grown in culture for 3 days.
Conditioned media from COS7 cells transfected with empty
vector alone, BMP4 plus empty vector, BMP4 plus CRIM1, or
BMP4 plus D2 were added to the cultures (Fig. 5, A–D). Kid-
neys grown in BMP4-conditioned media displayed reduced ure-
teric tree branching and reduced numbers of comma and S-
shaped bodies compared with kidneys grown in control or
CRIM1-conditioned media. BMP4 plus CRIM1-conditioned me-
dia showed a reduced BMP4 effect (Fig. 5, E and F), whereas
BMP4 plus CRIM1 D2-conditioned media showed an interme-
diate phenotype (Fig. 5F). Hence CRIM1 can ameliorate the
effect of BMP4. Removal of CRR1 and -2 decreases the ability
of CRIM1 to act in this way. Analysis of the conditioned media
by Western blotting and densitometric analysis (Fig. 5, G and
H) showed that the media from the CRIM1-expressing cells
contained less mature BMP4. These results support our other
analyses and suggest that in vivo the effect of CRIM1 on BMP
expression and secretion may result in a reduced concentration
of active mature BMPs available to the tissues.
DISCUSSION
Proteins containing chordin-like CRRs are an important and
growing family of extracellular regulators of the TGF super-
family. Most identified to date are secreted diffusible proteins,
such as CHRD and SOG, which inhibit BMP function. Unlike
CHRD and SOG, we have shown that CRIM1 is an N-glycosy-
lated transmembrane protein predominantly localized to the
cell membrane, but that a proportion of CRIM1 can be cleaved
and released from the cell membrane as a secreted ectodomain.
We also demonstrate that CRIM1 can interact intracellularly
with BMP4 or BMP7, supporting the hypothesis that it will act
as a mediator of TGF superfamily ligand activity, although
not defining the specific physiological ligand. Binding of Crim1
appears to affect BMP production in three ways. There is a
decrease in the production and processing of preprotein to
mature BMP, the secretion of mature BMP is reduced, and a
proportion of the BMP released from the cell remains associ-
ated with CRIM1, either tethered to the cell surface or as a
complex in the media. These represent novel modes of BMP
antagonism.
We have verified that it is the CRR repeats of CRIM1 that
mediate the binding of BMPs, because CRIM1 D2 (CRRs 1 and
2 deleted) and D4 (CRRs 3–6 deleted) interact only weakly with
BMP7. CHRD and other CRR-containing proteins bind to the
mature, secreted form of BMP via one or more CRR. Unlike
these proteins CRIM1 binds to pre-BMPs. However, because
the CRR repeats of CRIM1 are necessary for binding, it is likely
that interaction is still between the CRRs and the mature
domain of the dimeric BMP precursor.
The intracellular interaction of CRIM1 and BMPs appears to
be specific and not due to an artifact of overexpression. A
nonspecific interaction between CRIM1 and BMPs within the
cell would suggest the proteins were misfolded. However, the
editing machinery within the cell would target the misfolded
proteins for degradation within the ER (24). CRIM1 and BMP7
are clearly trafficked from the ER through the Golgi and can be
secreted. Furthermore, the two CRIM1 deletion constructs D2
and D4 interact with BMP7 only weakly, whereas GHR does
not interact with BMP7 at all. That BMP expression is reduced
in the presence of CRIM1 also appears to be specific for CRIM1,
because it does not occur with CRIM1 D2 or GHR.
The apparent role of CRIM1 in the retardation of ligand
secretion is not unique. The fibroblast growth factor receptor
(FGFR, also called E selectin) is localized both to the Golgi and
the cell membrane. Within the cell, FGFR inhibits the secretion
of its ligand, fibroblast growth factor (FGF), and maintains an
intracellular pool of FGF (25). Co-expression of CRIM1 with
BMPs resulted in the reduced production of BMPs. CRIM1 may
inhibit processing of pre-BMPs to BMPs and thereby target the
pre-BMPs for degradation or, like the FGFR, CRIM1 may se-
quester pre-BMPs into an intracellular pool that is limited in
capacity. Once the pool is full, further expression may be in-
hibited. Whatever the mechanism may be, the overall effect of
CRIM1 co-expression with BMPs is to reduce the amount of
active mature BMPs secreted into the media, effectively result-
ing in antagonism.
The function of tethering of BMPs to the cell surface by
Crim1 is unclear, as is the role of cleavage of the ectodomain.
Tethering by CRIM1 may act to increase the effective half-life
of BMPs by facilitating their slow and prolonged release from
the surface, may regulate the distance over which BMPs can
act, or may deliver BMPs to receptors on the cell surface.
Curiously, however, our biotinylation studies suggest that it is
the pre-BMP form of BMPs, which are tethered to the cell.
CRIM1 cleavage does appear to occur and complexes between
BMP and cleaved CRIM1 do exist in the media of co-transfected
cells. This might again support the concept of delivery to re-
ceptors on another cell, restriction of the distance over which
BMPs can act, or regulation of half-life in solution. Repression
of secretion, tethering, and binding to the ectodomain may
represent different actions tailored for different ligands. An-
other CRR-containing protein, connective tissue growth factor,
has already been shown to bind both TGF1 and BMP4, deliv-
ering the former to its receptor and therefore acting as a facil-
itator but antagonizing the binding of the latter, thereby acting
as an antagonist (18). It is possible that there are multiple
roles, both positive and negative, being played by Crim1 de-
pending upon the particular ligand bound. Further studies will
be needed to clarify the versatility of Crim1 with respect to
TGF superfamily ligand binding. However, these studies sug-
gest that Crim1, unlike the CRR-containing proteins previ-
ously described, may function by reducing the production and
secretion of active BMPs from the cells in which it is expressed.
This would provide a novel level of regulation of BMP action
during development and beyond.
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